Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Heier Jeffrey S. and Khanani Arshad M. and Ruiz Carlos Quezada and Basu Karen and Ferrone Philip J. and Brittain Christopher and Figueroa Marta S. and Lin Hugh and Holz Frank G. and Patel Vaibhavi and Lai Timothy Y. Y. and Silverman David and Tóth-Molnár Edit and Zatorska Barbara and Kollaborációs szervezet: TENAYA and LUCERNE Investigators: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
LANCET, 399 (10326). pp. 729-740. ISSN 0140-6736 (2022)

[thumbnail of TheLancet729-740.pdf]
Preview
Text
TheLancet729-740.pdf - Published Version

Download (834kB) | Preview
Creators:
Heier Jeffrey S.
Khanani Arshad M.
Ruiz Carlos Quezada
Basu Karen
Ferrone Philip J.
Brittain Christopher
Figueroa Marta S.
Lin Hugh
Holz Frank G.
Patel Vaibhavi
Lai Timothy Y. Y.
Silverman David
Tóth-Molnár Edit (kollab) MTMT
Zatorska Barbara
Kollaborációs szervezet: TENAYA and LUCERNE Investigators
Item Type: Journal Article
Journal or Publication Title: LANCET
Date: 2022
Volume: 399
Number: 10326
Page Range: pp. 729-740
ISSN: 0140-6736
Publisher: The Lancet Publishing Group
Faculty/Unit: Albert Szent-Györgyi Medical School
Institution: University of Szeged (2000-)
Language: English
MTMT rekordazonosító: 32786392
DOI azonosító: https://doi.org/10.1016/S0140-6736(22)00010-1
Date Deposited: 2022. Apr. 25. 15:56
Last Modified: 2022. Apr. 25. 15:56
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/24214
Web of Science® Times Cited: 341 View citing articles in Web of Science®

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year